What causes prostate cancer


milyen érzések a prosztatitisekkel

Men deaths due to cancer were more affected than women With deaths per inhabitants, Hungary recorded the highest age-standardised death rate from cancer among the EU Member States. High death rates from cancer were also registered in CroatiaSlovakia and Slovenia In contrast, low death rates from cancer were recorded in a number of Mediterranean and Nordic countries. The lowest rate was recorded in Cyprus with deaths from cancer per inhabitants, followed by FinlandMaltaSweden and Spain Over the period from tothe age-standardised death rate has fallen slowly but steadily, from deaths from cancer per inhabitants in to in This news item is published on the occasion of World Cancer Day 4 February.

soe krónikus prosztatitisben

The World Cancer Day aims to save millions of preventable deaths each year by raising awareness and education about cancer. For more information: Causes of death statistics are based on information derived from the medical certificate of cause of death.

lézer a prosztatában chelnyben

Causes of death statistics present absolute numbers, crude death rates and age- standardised death rates. As most causes of death vary significantly with people's age and sex, the use of standardised death rates improves comparability over time and between countries.

prosztata kezelés chaga

For more information on the statistics available in this area, take a look at the overview of health statistics and the Statistics Explained article Health statistics introduced. Further information is published here.

a prostatitis cpeam kezelése

To contact us, please visit our User Support page. For press queries, please contact our Media Support.

Share this page: We are sorry to hear that. What causes prostate cancer can report the issue here.

Clin Cancer Res ; 27 7 :04 However, a significant subset of patients is ineligible to receive cisplatin-based therapy due to medical contraindications, and no NER-targeted approaches are available for platinum-ineligible or platinum-refractory ERCC2-mutant cases. In addition, we used available clinical and sequencing data from multiple urothelial tumor cohorts to develop and validate a composite mutational signature of ERCC2 deficiency and cisplatin sensitivity.

Thank you for the information. We will investigate the issue.

salt prostate

Was this page useful?